Filters: Keyword is Opioid-Related Disorders [Clear All Filters]
"Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes." Drug and alcohol dependence 131, no. 1-2 (2013): 127-35. Abstract
"Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?" CNS drugs 22, no. 2 (2008): 99-111. Abstract
"Evaluation of a combined online and in person training in the use of buprenorphine." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 27, no. 3 (2006): 39-45. Abstract
"Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial." Addictive behaviors 35, no. 5 (2010): 537-40. Abstract
"Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997-2007." Drug and alcohol dependence 115, no. 3 (2011): 221-8. Abstract
"Social and structural aspects of the overdose risk environment in St. Petersburg, Russia." The International journal on drug policy 20, no. 3 (2009): 270-6. Abstract
"Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States." Addiction (Abingdon, England) 103, no. 6 (2008): 979-89. Abstract
"Illicit use of opioids: is OxyContin a "gateway drug"?" The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 16, no. 3 (2007): 166-73. Abstract
"Oral substitution treatment of injecting opioid users for prevention of HIV infection." Cochrane database of systematic reviews (Online), no. 8 (2011): CD004145. Abstract
"Substitution treatment of injecting opioid users for prevention of HIV infection." Cochrane database of systematic reviews (Online), no. 2 (2008): CD004145. Abstract
"Update in addiction medicine for the generalist." Journal of general internal medicine 22, no. 8 (2007): 1190-4.
"Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction." AIDS (London, England) 19, no. 15 (2005): 1635-41. Abstract
"Integration of buprenorphine for substance-abuse treatment by HIV care providers." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S1-2.
"Clinical practice. Office-based treatment of opioid-dependent patients." The New England journal of medicine 347, no. 11 (2002): 817-23.
"Guideline development for office-based pharmacotherapies for opioid dependence." Journal of addictive diseases 22, no. 4 (2003): 109-20. Abstract
"Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 17, no. 2 (2008): 116-20. Abstract
"Consensus statement on office-based treatment of opioid dependence using buprenorphine." Journal of substance abuse treatment 27, no. 2 (2004): 153-9. Abstract
"Buprenorphine: effective treatment of opioid addiction starts in the office." American family physician 73, no. 9 (2006): 1513-4.
"Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S33-8. Abstract
"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence." The New England journal of medicine 355, no. 4 (2006): 365-74. Abstract
"Coordination of medical care and opioid dependence treatment in primary care: a case report." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 24, no. 1 (2003): 43-6.
"Substance use of disorders in HIV-infected patients: impact and new treatment strategies." Topics in HIV medicine : a publication of the International AIDS Society, USA 12, no. 3 (2004): 77-82. Abstract
"Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 13 Suppl 1 (2004): S67-78. Abstract
"Opioid dependence: rationale for and efficacy of existing and new treatments." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S173-7. Abstract
"Treatment of adolescent opioid dependence: no quick fix." JAMA : the journal of the American Medical Association 300, no. 17 (2008): 2057-9.
"New federal initiatives to enhance the medical treatment of opioid dependence." Annals of internal medicine 137, no. 8 (2002): 688-92. Abstract
"Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 11, no. 2 (2002): 111-23. Abstract
"A staging system to predict prognosis among methadone maintenance patients, based on admission characteristics." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 23, no. 4 (2002): 233-44. Abstract
"Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians." Journal of addiction medicine 6, no. 2 (2012): 159-65. Abstract
"HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment." Journal of addiction medicine 7, no. 6 (2013): 410-6. Abstract
"Within-prison drug injection among HIV-infected male prisoners in Indonesia: a highly constrained choice." Drug and alcohol dependence 149 (2015): 71-9. Abstract
"Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence." The American journal of drug and alcohol abuse 33, no. 5 (2007): 643-54. Abstract
"Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females." The pharmacogenomics journal 14, no. 3 (2014): 303-8. Abstract
"Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence." Journal of substance abuse treatment 33, no. 4 (2007): 411-5. Abstract
"Lifetime ATS use and increased HIV risk among not-in-treatment opiate injectors in Malaysia." Drug and alcohol dependence 124, no. 1-2 (2012): 177-80. Abstract
"Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms." Journal of substance abuse treatment 29, no. 4 (2005): 307-12. Abstract
"Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S14-21. Abstract
"Assessing social risks prior to commencement of a clinical trial: due diligence or ethical inflation?" The American journal of bioethics : AJOB 9, no. 11 (2009): 48-54. Abstract
"Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication." The American journal of drug and alcohol abuse 38, no. 3 (2012): 206-12. Abstract
"Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone." The American journal of drug and alcohol abuse 37, no. 4 (2011): 224-8. Abstract
"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market." The American journal of drug and alcohol abuse 35, no. 2 (2009): 68-72. Abstract
"HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications." The International journal on drug policy 18, no. 4 (2007): 326-8. Abstract
"Lessons from Tanzania on the integration of HIV and tuberculosis treatments into methadone assisted treatment." The International journal on drug policy 25, no. 1 (2014): 22-5. Abstract
"Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al." Journal of acquired immune deficiency syndromes (1999) 58, no. 4 (2011): e112; author reply e112-3.
"Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance." Antimicrobial agents and chemotherapy 57, no. 12 (2013): 6154-7. Abstract
"Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone." Drug and alcohol dependence 105, no. 3 (2009): 234-9. Abstract
"Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases." The American journal of drug and alcohol abuse 33, no. 6 (2007): 869-74. Abstract
"Nonmedical use of opioid analgesics obtained directly from physicians: prevalence and correlates." Archives of internal medicine 171, no. 11 (2011): 1034-6.
"Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates." Drug and alcohol dependence 94, no. 1-3 (2008): 38-47. Abstract
"Opioid use disorder in the United States: insurance status and treatment access." Drug and alcohol dependence 94, no. 1-3 (2008): 207-13. Abstract
